The global multi-cancer early detection market is growing rapidly, driven by rising awareness of early diagnosis benefits and increasing collaborations between healthcare companies and research institutions. These partnerships are accelerating the development and adoption of advanced early detection technologies. For example, the collaboration between HCA Healthcare, Sarah Cannon Cancer Institute, and GRAIL highlights the industry's focus on improving outcomes and reducing costs through early intervention.
According to BIS Research the global multi-cancer early detection market is projected to grow from $1,138.3 million in 2024 to $5,153.5 million by 2034, at a CAGR of 16.30%. This growth is driven by the rising cancer burden, demand for early diagnosis, and advances in liquid biopsy, genomics, and blood-based screening technologies. Increased investment in precision medicine and preventive healthcare further supports market expansion.
Get to Know More Insights on Market Growth and Key Players Download Sample Report Here!
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Other Technologies
• Blood
• Saliva and Buccal Swab
• Others
• Hospital
• Research Institutes
• Others
• North America
o U.S.
o Canada
• Europe
o Germany
o U.K.
o France
o Italy
o Spain
o Rest-of-Europe
• Asia-Pacific
o China
o Japan
o India
o Rest-of-Asia-Pacific
• Rest-of-the-World
Recent partnerships are accelerating progress in multi-cancer early detection. In October 2024, Lucence teamed up with A*STAR’s DxD Hub to adapt its LucenceINSIGHT test for broader use, enhancing accessibility. Grail and BeniComp launched Galleri for eligible BeniComp Select members in January 2024, supporting preventive health efforts. In April 2023, Singlera Genomics and Clinomics USA partnered to globally offer early cancer detection tests like ColonES and PanSeer through Clinomics’ CLIA Lab.
Access More Insights on Multi-Cancer Early Detection Market
The rising global cancer burden, with cases projected to reach 24.1 million by 2030, is driving demand for early detection. Detecting cancers like breast, lung, and colorectal at early stages improves survival rates and reduces treatment complexity, fueling growth in multi-cancer early detection solutions.
High costs and limited insurance coverage make multi-cancer early detection tests less accessible. These barriers limit adoption, particularly in lower-income populations and public healthcare systems.
AI integration is enhancing accuracy, speed, and cost-effectiveness in early cancer detection by combining blood tests, imaging, and genetic analysis into unified diagnostic platforms.
According to Swati Sood, Principal Analyst at BIS Research, the multi-cancer early detection market is set for strong growth, driven by rising cancer incidence, increased adoption of liquid biopsy, and growing public awareness. Advances in screening technologies and data-driven healthcare are enhancing early diagnosis, improving survival rates, and expanding clinical adoption.
Explore BIS Research’s tailored Go-to-Market Strategy that helps businesses explore and enter emerging markets, promising professional guidance to unlock new opportunities.
